- Home
- STOK vs NBXG Comparison
STOK vs NBXG Comparison
Compare STOK & NBXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STOK
- NBXG
- Stock Information
- Founded
- STOK 2014
- NBXG 2021
- Country
- STOK United States
- NBXG United States
- Employees
- STOK N/A
- NBXG N/A
- Industry
- STOK Biotechnology: Pharmaceutical Preparations
- NBXG Trusts Except Educational Religious and Charitable
- Sector
- STOK Health Care
- NBXG Finance
- Exchange
- STOK Nasdaq
- NBXG Nasdaq
- Market Cap
- STOK 1.3B
- NBXG 1.1B
- IPO Year
- STOK 2019
- NBXG N/A
- Fundamental
- Price
- STOK $22.74
- NBXG $15.18
- Analyst Decision
- STOK Strong Buy
- NBXG
- Analyst Count
- STOK 6
- NBXG 0
- Target Price
- STOK $26.60
- NBXG N/A
- AVG Volume (30 Days)
- STOK 893.3K
- NBXG 243.7K
- Earning Date
- STOK 11-04-2025
- NBXG 01-01-0001
- Dividend Yield
- STOK N/A
- NBXG 10.25%
- EPS Growth
- STOK N/A
- NBXG N/A
- EPS
- STOK 0.91
- NBXG N/A
- Revenue
- STOK $199,893,000.00
- NBXG N/A
- Revenue This Year
- STOK $416.54
- NBXG N/A
- Revenue Next Year
- STOK N/A
- NBXG N/A
- P/E Ratio
- STOK $25.02
- NBXG N/A
- Revenue Growth
- STOK 1218.82
- NBXG N/A
- 52 Week Low
- STOK $5.35
- NBXG $9.31
- 52 Week High
- STOK $24.60
- NBXG $12.23
- Technical
- Relative Strength Index (RSI)
- STOK 73.55
- NBXG 65.40
- Support Level
- STOK $18.80
- NBXG $15.07
- Resistance Level
- STOK $24.60
- NBXG $15.24
- Average True Range (ATR)
- STOK 1.23
- NBXG 0.17
- MACD
- STOK 0.02
- NBXG 0.03
- Stochastic Oscillator
- STOK 67.93
- NBXG 90.14
About STOK Stoke Therapeutics Inc.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
About NBXG Neuberger Berman Next Generation Connectivity Fund Inc.
Neuberger Berman Next Generation Connectivity Fund Inc. is a non-diversified, closed-end management investment company. The fund's investment objectives are to provide capital appreciation and income. Under normal market conditions, the Fund will invest at least 80% of its total assets in equity securities issued by U.S. and non-U.S. companies, in any market capitalization range, that is relevant to the theme of investing in "NextGen Companies".